- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06663423
Impact of Anxiety and Depression on Implicit and Explicit Memory Performance (ADEM)
Cohort Study on the Differential Impact of Anxiety and Depression on Implicit and Explicit Memory Performance
This study examines the effect of anxiety and depression on memory processes, focusing on implicit and explicit memory. Implicit memory involves unconscious recall, such as recognizing familiar words without effort, while explicit memory requires conscious recollection of specific information. The study aims to investigate whether individuals with depression and anxiety show differences in these types of memory, which may contribute to biases related to their emotional states.
Participants were divided into three groups: individuals with depressive disorder, individuals with generalized anxiety disorder, and a control group with no emotional disorders. Each group was assessed using tasks designed to measure both implicit and explicit memory performance. The goal is to enhance understanding of memory biases in individuals with depression and anxiety, potentially supporting more targeted interventions.
Study Overview
Status
Detailed Description
This cohort study is designed to explore potential memory biases in individuals with depressive and anxiety disorders compared to a control group. The study includes 27 participants divided into three groups: nine individuals diagnosed with major depressive disorder, nine with generalized anxiety disorder, and nine control subjects with no history of emotional disorders. All participants were matched by age and education level.
Participants completed standardized tasks and assessments, including the Spielberger State-Trait Anxiety Inventory and various memory tasks such as word decoding and recognition memory tasks. These tasks aim to evaluate mood-congruent biases in memory recall. Data collection will focus on analyzing any distinct memory processing patterns in depression and anxiety to improve psychological treatment approaches.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Tehran, Iran, Islamic Republic of, 14176
- Tehran Institute of Psychiatry and/or Shahid Esmaili Clinic.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adults aged 18 years or older
- Individuals diagnosed with major depressive disorder (Group 1)
- Individuals diagnosed with generalized anxiety disorder (Group 2)
- Healthy individuals with no history of emotional disorders (Group 3)
Exclusion Criteria:
- History of neurological disorders
- Visual impairments
- Substance abuse or drug addiction
- Psychiatric hospitalizations unrelated to primary diagnosis (for Groups 1 and 2)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Group 1
Depressive Disorder group - 9 participants.
|
|
Group 2
Generalized Anxiety Disorder group - 9 participants.
|
|
Group 3
Control group - 9 participants.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Explicit Memory Bias
Time Frame: At a single time point during the experimental session, approximately 1 day
|
The primary outcome is to assess explicit memory bias by measuring word recognition in participants with depressive disorder, generalized anxiety disorder, and a control group.
Word recognition accuracy and response times are evaluated to determine mood-congruent biases specific to each group.
|
At a single time point during the experimental session, approximately 1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Implicit Memory Bias
Time Frame: At a single time point during the experimental session, approximately 1 hour
|
Secondary outcome is to assess implicit memory bias using a tachistoscopic word recognition task, measuring participants' ability to identify emotionally congruent words (e.g., words associated with depression, anxiety, and neutral words) without conscious awareness.
|
At a single time point during the experimental session, approximately 1 hour
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mood Congruence in Recognition Performance
Time Frame: At a single time point during the experimental session, approximately 1 hour
|
Analysis of mood-congruent recognition performance across different emotional word types (depression-related, anxiety-related, pleasant, and neutral) to determine if participants show selective attention based on mood.
|
At a single time point during the experimental session, approximately 1 hour
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SDU-MEMORY-2024
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder (MDD)
-
Yonggui YuanNot yet recruitingMajor Depressive Disorder (MDD)China
-
Daniel LindqvistLund University; KetabonRecruitingMajor Depressive Disorder (MDD)Sweden
-
King's College LondonCardiff and Vale University Health Board; South London and Maudsley NHS Foundation... and other collaboratorsRecruitingMajor Depressive Disorder (MDD)United Kingdom
-
Supernus Pharmaceuticals, Inc.RecruitingMajor Depressive Disorder (MDD)United States
-
University of PennsylvaniaRecruiting
-
University of PretoriaNot yet recruitingMajor Depressive Disorder (MDD)Saudi Arabia
-
Shanghai Mental Health CenterLingang National LaboratoryNot yet recruitingMajor Depressive Disorder (MDD
-
Tel Aviv UniversityNot yet recruitingMajor Depressive Disorder (MDD)Israel
-
Sichuan Purity Pharmaceutical Technology Co., Ltd.Recruiting
-
The Second Hospital of Anhui Medical UniversityNot yet recruiting